Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

1 hour ago 2

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 2:01 PM CDT 4 min read

On May 15, 2026, HighVista Strategies disclosed a acquisition of 96,218 shares of Tyra Biosciences (NASDAQ:TYRA), estimated astatine $3.11 cardinal based connected quarterly mean pricing.

What happened

According to its SEC filing dated May 15, 2026, HighVista Strategies accrued its presumption successful Tyra Biosciences by 96,218 shares implicit the erstwhile quarter. The estimated transaction worth was $3.11 million, calculated utilizing the mean closing terms for the quarter. The worth of the presumption astatine quarter-end roseate by $4.11 million, a fig that includes some the further shares acquired and banal terms appreciation.

What other to cognize

HighVista’s determination was a buy, making Tyra Biosciences 1.39% of its 13F AUM aft the trade.
Top 5 holdings aft the filing:
- NYSEMKT: DBC: $30.61 cardinal (8.5% of AUM)
- NASDAQ: ABVX: $12.61 cardinal (3.5% of AUM)
- NASDAQ: PRAX: $8.48 cardinal (2.3% of AUM)
- NASDAQ: COGT: $7.58 cardinal (2.1% of AUM)
- NASDAQ: SYRE: $7.38 cardinal (2.0% of AUM)
As of May 14, 2026, Tyra Biosciences shares were priced astatine $36.51, up 280% implicit the past twelvemonth and outperforming the S&P 500 by 250 percent points.

Company overview

Metric

Value

Price (as of marketplace adjacent May 14, 2026)	$36.51
Market capitalization	$2.11 billion
Net income (TTM)	($119.9 million)
1-year terms change	280%

Company snapshot

Tyra Biosciences develops targeted therapies for crab and uncommon diseases, with a pb campaigner (TYRA-300) focused connected FGFR3 inhibition successful musculus invasive bladder cancer; further pipeline programs code FGFR2-driven cholangiocarcinoma, FGFR3-related achondroplasia, RET kinase, and FGFR4-related cancers.
The steadfast operates a preclinical-stage biopharmaceutical model, generating worth done proprietary R&D and leveraging the SNAP level for accelerated molecular design; presently has nary merchandise gross arsenic of the latest reporting period.
It targets oncologists, healthcare providers, and patients affected by cancers and familial disorders linked to fibroblast maturation origin receptors, with a absorption connected addressing tumor absorption and improving diligent outcomes.

Tyra Biosciences is simply a preclinical-stage biotechnology institution specializing successful precision therapies for crab and uncommon familial diseases. The institution utilizes its proprietary SNAP level to accelerate cause find and design, aiming to flooded absorption mechanisms successful oncology. With a focused pipeline and a scalable probe approach, Tyra seeks to found a competitory borderline successful targeted oncology therapeutics.

What this transaction means for investors

Tyra shares person already surged astir 280% implicit the past year, but HighVista’s determination to adhd vulnerability suggests immoderate investors deliberation the company’s upcoming objective catalysts could warrant adjacent higher expectations.

The steadfast has spent the twelvemonth aggressively advancing what absorption calls its “dabogratinib 3x3” strategy, pursuing perchance pivotal studies crossed 3 large indications tied to FGFR3 biology. It precocious dosed the archetypal diligent successful its SURF303 survey for low-grade precocious tract urothelial carcinoma, portion further Phase 2 information from bladder crab and achondroplasia programs are expected aboriginal this year.

Meanwhile, the institution ended the archetypal 4th with astir $383.5 cardinal successful cash, currency equivalents, and marketable securities, which absorption says should money operations into the 2nd fractional of 2028.

Ultimately, Tyra is progressively transitioning from an early-stage level communicative to a catalyst-driven objective one, and if upcoming information proceed to validate dabogratinib crossed aggregate indications, investors could commencement viewing the institution little similar a speculative biotech and much similar a aboriginal commercialized oncology player.

Read Entire Article